Sign inJoin waitlistJoin the waitlist

JR

Jaclyn Rosenzweig

Assistant Professor of Pediatrics · Cornell Univ Joan and Sanford I Weill Med Coll

Credentials: · ·

History

Cornell Univ Joan and Sanford I Weill Med Coll · New York Presbyterian Hospital
Present

Pediatric Hematology/Oncology
New York Presbyterian Hospital
2019–2022
Pediatrics
New York Presbyterian Hospital
2016–2019
Univ of Miami Leonard M. Miller Sch of Med
2012–2016
Emory University
2008–2012

Research

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
Blood Advances · 2023 · 6 citations
A five year retrospective study of short term respiratory support outcomes for infants who received tracheostomy before one year of age
International Journal of Pediatric Otorhinolaryngology · 2015 · 5 citations
Acute myeloid leukemia with an MN1-ETV6 fusion in a young child with Down syndrome
Case report · Cold Spring Harbor molecular case studies · 2022 · First of 9 authors · 2 citations

Sheila McThenia
2 papers · 1 as a fellow
SK
Shipra Kaicker
2 papers
AY
Adam Yan
1 paper
AL
Alexandre Lucas
1 paper
Branko Cuglievan
1 paper
Christina Fong
1 paper
CF
Christopher Forlenza
1 paper
DW
David Wuest
1 paper
Elizabeth Cottrill
1 paper · 1 as a resident
ES
Emily Slotkin
1 paper
HD
Hema Dave
1 paper
Ilia Buhtoiarov
1 paper

Clinical trials

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2020–2028
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Site PI · Recruiting · Phase 3
Children's Oncology Group
2019–2032